Frequently
Asked Questions
Technology
Services
Partnerships
· What is Vega BioImaging's core technology?
Our technology uses functionalized alloy nanoparticles for direct protein detection, providing highly accurate quantification of biomarkers without the need for secondary antibodies.
· What services does Vega BioImaging offer?
We specialize in developing companion diagnostics (CDx) for pharmaceutical companies, supporting both new drug development and enhancing existing drug efficacy.
· How can Vega BioImaging's CDx development services benefit my company?
Our technology uses functionalized alloy nanoparticles for direct protein detection, providing highly accurate quantification of biomarkers without the need for secondary antibodies.
· What are the advantages of your technology over traditional methods?
Our platform offers higher precision, quantitative results, multiplexed biomarker detection, and automated AI-powered analysis, improving diagnostic reliability and efficiency.
· How can I partner with Vega BioImaging?
Contact us to discuss how our advanced diagnostic technology can support your precision medicine initiatives and improve patient outcomes.
· What are the early results of your technology?
Early research, in collaboration with the CRCHUM, indicates that our platform can differentiate protein expression with greater precision than traditional methods, with promising results expected by summer 2025.
· What is the impact of eliminating secondary antibodies in your diagnostic process?
Eliminating secondary antibodies enhances detection accuracy and specificity, providing a more reliable and precise quantification of protein expression.
· Who can benefit from Vega BioImaging's services?
Pharmaceutical companies developing new drugs, researchers seeking better diagnostic tools, and healthcare providers aiming to improve patient outcomes with precision medicine.